Comparative Pharmacology
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus UCEPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus UCEPHAN.
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) vs UCEPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
UCEPHAN (eculizumab) is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing the formation of the membrane attack complex (MAC) and terminal complement-mediated cell lysis.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
500 mg orally every 12 hours or 250 mg orally every 8 hours.
None Documented
None Documented
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
Terminal elimination half-life is 2.1 ± 0.5 hours in adults with normal renal function; prolonged to 20–50 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Approximately 70–80% of an administered dose is eliminated unchanged in urine via glomerular filtration and tubular secretion; the remainder (20–30%) is eliminated via biliary/fecal routes, with <5% as metabolites.
Category D/X
Category C
Antibiotic
Antibiotic, Cephalosporin